Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
J Endocrinol Invest (2017) 40(3):2817
WADA Prohibition The World Anti-Doping Agency classification for these peptides: GLP3 likely classified under prohibited substances as a GLP-1 receptor agonist Cagrilintide status as amylin analog may fall under peptide hormone prohibitions Combined formulation would be prohibited under multiple substance categories No Therapeutic Use Exemptions (TUEs) available for either component Detection methods under development for anti-doping testing WADAs position reflects that these remain investigational agents without regulatory approval from health authorities worldwide
One is that GLP-1 therapies can be used by adults, excluding pregnant people, for long-term treatment of obesity
Key Areas of Research Focus
This research theorized that nutrients presented in their naturally grown forms supply cofacters that make them more bioavailable, biologically active, and therefore more effective than nutrients that are isolated
